BIOMAT Database Logo BIOMAT Database Logo

Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. 2004

Martine E D Chamuleau, and Yuri Souwer, and S Marieke Van Ham, and Adri Zevenbergen, and Theresia M Westers, and Johannes Berkhof, and Chris J L M Meijer, and Arjan A van de Loosdrecht, and Gert J Ossenkoppele
Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands. m.chamuleau@vumc.nl

Effective antitumor responses need the activation of CD4+ T cells. MHC class II antigen presentation requires the release of class II-associated invariant chain peptide (CLIP) from the antigen-binding site. In antigen-presenting cells, human leukocyte antigen DM (HLA-DM; abbreviated DM in this article) catalyzes CLIP dissociation. In B cells, HLA-DO (DO) down-modulates DM function. Cell surface CLIP:HLA-DR (DR) ratio correlates to DO:DM ratio and the efficacy of antigen presentation. We examined 111 blood and bone marrow samples of patients with newly diagnosed acute myeloid leukemia (AML) for the expression of CLIP, DR, DM, and DO by flow cytometry. Patients with DR+/CLIP- blasts had a significant longer disease-free survival than patients with DR+/CLIP+ blasts. DO, until now believed to be restricted to lymphoid cells, could be demonstrated at protein level as well as by reverse transcription-PCR. DO:DM ratio correlated to CLIP:DR ratio, suggesting that, unlike in other antigen-presenting cells of the nonlymphoid cell type, both DO and DM mediate regulation of CLIP expression in AML blasts. We hypothesize that DR+/CLIP- AML blasts are able to present leukemia-specific antigens to CD4+ T helper cells initiating an effective and long-lasting antitumor response resulting in a prolonged disease-free survival.

UI MeSH Term Description Entries
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006681 HLA-D Antigens Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology. Antigens, HLA-D,Class II Human Antigens,HLA-Dw Antigens,Human Class II Antigens,Ia-Like Antigens, Human,Immune Response-Associated Antigens, Human,Immune-Associated Antigens, Human,Immune-Response Antigens, Human,HLA-D,HLA-Dw,Immune Response Associated Antigens, Human,Antigens, HLA D,Antigens, HLA-Dw,Antigens, Human Ia-Like,Antigens, Human Immune-Associated,Antigens, Human Immune-Response,HLA D Antigens,HLA Dw Antigens,Human Ia-Like Antigens,Human Immune-Associated Antigens,Human Immune-Response Antigens,Ia Like Antigens, Human,Immune Associated Antigens, Human,Immune Response Antigens, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Martine E D Chamuleau, and Yuri Souwer, and S Marieke Van Ham, and Adri Zevenbergen, and Theresia M Westers, and Johannes Berkhof, and Chris J L M Meijer, and Arjan A van de Loosdrecht, and Gert J Ossenkoppele
High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.
June 2014, Leukemia research,
Martine E D Chamuleau, and Yuri Souwer, and S Marieke Van Ham, and Adri Zevenbergen, and Theresia M Westers, and Johannes Berkhof, and Chris J L M Meijer, and Arjan A van de Loosdrecht, and Gert J Ossenkoppele
Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
April 2011, Cancer research,
Martine E D Chamuleau, and Yuri Souwer, and S Marieke Van Ham, and Adri Zevenbergen, and Theresia M Westers, and Johannes Berkhof, and Chris J L M Meijer, and Arjan A van de Loosdrecht, and Gert J Ossenkoppele
Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
February 1999, Journal of immunology (Baltimore, Md. : 1950),
Martine E D Chamuleau, and Yuri Souwer, and S Marieke Van Ham, and Adri Zevenbergen, and Theresia M Westers, and Johannes Berkhof, and Chris J L M Meijer, and Arjan A van de Loosdrecht, and Gert J Ossenkoppele
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.
December 2008, Haematologica,
Martine E D Chamuleau, and Yuri Souwer, and S Marieke Van Ham, and Adri Zevenbergen, and Theresia M Westers, and Johannes Berkhof, and Chris J L M Meijer, and Arjan A van de Loosdrecht, and Gert J Ossenkoppele
Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
June 1996, Journal of immunology (Baltimore, Md. : 1950),
Martine E D Chamuleau, and Yuri Souwer, and S Marieke Van Ham, and Adri Zevenbergen, and Theresia M Westers, and Johannes Berkhof, and Chris J L M Meijer, and Arjan A van de Loosdrecht, and Gert J Ossenkoppele
Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation.
March 2012, Oncoimmunology,
Martine E D Chamuleau, and Yuri Souwer, and S Marieke Van Ham, and Adri Zevenbergen, and Theresia M Westers, and Johannes Berkhof, and Chris J L M Meijer, and Arjan A van de Loosdrecht, and Gert J Ossenkoppele
TNF-alpha receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells.
June 2004, Leukemia,
Martine E D Chamuleau, and Yuri Souwer, and S Marieke Van Ham, and Adri Zevenbergen, and Theresia M Westers, and Johannes Berkhof, and Chris J L M Meijer, and Arjan A van de Loosdrecht, and Gert J Ossenkoppele
Clinical significance of MHC class II-associated invariant chain expression in human gastric carcinoma.
October 2005, Oncology reports,
Martine E D Chamuleau, and Yuri Souwer, and S Marieke Van Ham, and Adri Zevenbergen, and Theresia M Westers, and Johannes Berkhof, and Chris J L M Meijer, and Arjan A van de Loosdrecht, and Gert J Ossenkoppele
Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia.
December 2014, Oncoimmunology,
Martine E D Chamuleau, and Yuri Souwer, and S Marieke Van Ham, and Adri Zevenbergen, and Theresia M Westers, and Johannes Berkhof, and Chris J L M Meijer, and Arjan A van de Loosdrecht, and Gert J Ossenkoppele
[Expression of HLA class II antigen-associated invariant chain on renal cell cancer].
June 1993, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
Copied contents to your clipboard!